Dova Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for DOPTELET® (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP)

June 27, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search